Pulse Biosciences, Inc (NASDAQ:PLSE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $45.25.

Several brokerages have recently issued reports on PLSE. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, September 6th. Needham & Company LLC initiated coverage on Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 price target for the company. Finally, Canaccord Genuity Group lifted their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th.

Pulse Biosciences Stock Performance

Shares of PLSE stock opened at $54.43 on Friday. The stock has a market cap of $3.77 billion, a PE ratio of -46.13 and a beta of 1.63. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $58.90. The stock has a fifty day moving average price of $39.87 and a 200 day moving average price of $28.84.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The business had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.53 million. As a group, equities research analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current year.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,001 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were bought at an average cost of $49.95 per share, with a total value of $49,999.95. Following the transaction, the chief operating officer directly owned 4,095 shares in the company, valued at approximately $204,545.25. This trade represents a 32.35% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders purchased 4,095 shares of company stock worth $199,931. 74.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Bank of America Corp DE lifted its holdings in shares of Pulse Biosciences by 8.2% in the 1st quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock worth $18,698,000 after purchasing an additional 65,884 shares during the last quarter. Deutsche Bank AG acquired a new stake in Pulse Biosciences in the second quarter worth about $687,000. Legal & General Group Plc acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $395,000. Panoramic Capital LLC bought a new position in Pulse Biosciences during the 2nd quarter valued at $2,719,000. Finally, BlackRock Inc. bought a new position in Pulse Biosciences during the second quarter valued at about $40,672,000. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.